KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to $201.6 million.

  • Halozyme Therapeutics' Cash from Investing Activities rose 22037.58% to $201.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.5 million, marking a year-over-year increase of 17502.81%. This contributed to the annual value of -$262.7 million for FY2024, which is 17110.28% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Cash from Investing Activities stood at $201.6 million for Q3 2025, which was up 22037.58% from $84.8 million recorded in Q2 2025.
  • Halozyme Therapeutics' Cash from Investing Activities' 5-year high stood at $201.6 million during Q3 2025, with a 5-year trough of -$434.9 million in Q2 2022.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$44.6 million (2021), whereas its average is -$55.6 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Cash from Investing Activities plummeted by 817876.98% in 2023 and then skyrocketed by 45556.63% in 2024.
  • Over the past 5 years, Halozyme Therapeutics' Cash from Investing Activities (Quarter) stood at -$299.5 million in 2021, then soared by 99.42% to -$1.7 million in 2022, then crashed by 374.86% to -$8.3 million in 2023, then surged by 455.57% to $29.5 million in 2024, then skyrocketed by 583.88% to $201.6 million in 2025.
  • Its last three reported values are $201.6 million in Q3 2025, $84.8 million for Q2 2025, and -$90.4 million during Q1 2025.